Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery

Area of Science:

• Pharmaceutical Nanotechnology
• Antiretroviral Drug Development
• Pharmacokinetics and Drug Delivery

Background:

• Reverse transcriptase inhibitors are crucial components of highly active antiretroviral treatments.
• Current nucleoside and non-nucleoside agents face challenges including poor solubility, stability, and unfavorable pharmacokinetics.
• These limitations hinder the efficacy of existing antiretroviral therapies.

Purpose of the Study:

• To analyze nanotechnology applications for improving reverse transcriptase inhibitor drug properties.
• To evaluate the potential of nanosystems in overcoming limitations of current antiretroviral agents.
• To assess the impact of nanocarriers on drug solubility, distribution, bioavailability, and stability.

Main Methods:

• In-depth literature review of nanotechnology applications for reverse transcriptase inhibitors.
• Examination of clinically used nucleoside and non-nucleoside reverse transcriptase inhibitors.
• Analysis of supramolecular vesicular systems including liposomes, niosomes, and solid lipid nanoparticles.

Main Results:

• Incorporation into nanosystems significantly improves solubility and bioavailability of reverse transcriptase inhibitors.
• Nanosystems enhance drug distribution and stability, addressing key pharmacokinetic drawbacks.
• Vesicular systems like liposomes and niosomes effectively overcome limitations of antiretroviral agents.

Conclusions:

• Nanotechnology offers a promising strategy to enhance the performance of reverse transcriptase inhibitors.
• Nanosystems can significantly improve the therapeutic efficacy of antiretroviral drugs.
• Further development of nanomedicines holds potential for advancing HIV treatment.